Ainos SARS-CoV-2 Antigen Rapid Test
COVID-19
Key Facts
About Ainos
Ainos is a publicly traded medtech company undergoing a strategic transformation from its 1984 roots in low-dose interferon research into a diversified AI-driven healthcare player. Its core technology platform is the 'AI Nose,' a semiconductor-based sensor array that analyzes VOCs from breath and other samples to create a digital 'Smell ID' for disease detection. The company's pipeline includes rapid diagnostic tests for COVID-19 and pneumonia, a non-invasive feminine health test, and several clinical-stage low-dose interferon programs for conditions like thrombocytopenia and Sjögren's Syndrome. With over 60 patents and a focus on telehealth-friendly devices, Ainos aims to commercialize its platforms in the growing digital health and point-of-care testing markets.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |
| UOL COVID-19 Test | Uh-Oh Labs | Approved |
| Lagevrio (molnupiravir) | Ridgeback Biotherapeutics | Approved/EUA |
| CVXGA | CyanVac | Phase 2 |
| SARS-CoV-2 Test | NanoPin Technologies | Commercial (LDT) |
| Emeramide for COVID-19 | EmeraMed | Preclinical |
| COVID-19 Oral Therapeutic (with Sen-Jam Pharmaceutical) | KVK Tech | Development |